https://doi.org/10.55788/b4e55b17
“We all see patients that have their medication list littered with dietary supplements and, in fact, over 3 quarters of Americans take a dietary supplement, and 18% of those individuals take a supplement to promote heart health,” Dr Luke Laffin (Cleveland Clinic, OH, USA) explained [1]. The presented SPORT trial (NCT04846231) evaluated the effect of low-dose statin treatment of 5 mg rosuvastatin on lipids and inflammatory biomarkers compared with six widely used dietary supplements (fish oil, cinnamon, garlic, turmeric, plant sterols or red yeast rice) and placebo. Within the prospective, randomised, single-blinded trial, 199 participants were equally allocated to 1 of the 8 study arms. Laboratory testing (days 0 and 28) included analysis of a lipid and comprehensive metabolic panel, and highly sensitive (hs)CRP levels. The primary endpoint was the proportion of change in LDL-C.
“Study participants were in their mid-60s, we enrolled 60% women, the median 10-year atherosclerotic cardiovascular disease (ASCVD) risk was 7.9%, mean LDL-C was 128 mg/dL, and most people had relatively normal or low CRP,” Dr Laffin described the SPORT cohort. Analysis of the change in LDL-C showed a -37.86% reduction in LDL-C for rosuvastatin, a significantly greater reduction than was reported for placebo (-2.63%) or any of the supplements (ranging between -6.55 and +5.13; P<0.001 for all comparisons). The results for change in total cholesterol (P<0.001) and triglycerides (P<0.05) were similarly superior in the rosuvastatin arm for all evaluations. HsCRP levels did not differ between the statin arm and the other groups.
“None of the supplements decreased LDL-C compared with placebo and the garlic supplement even increased LDL-C by almost 8% (P=0.01),” Dr Laffin commented on the values for biomarker results of the supplement arms versus the placebo group. Plant sterols significantly decreased HDL-C versus placebo (-7.1%; P=0.02). Additional comparisons did not yield significant results for change in total cholesterol, triglycerides or hsCRP.
“Adverse events were numerically similar across all study groups, and slightly higher with some of the supplements, particularly for plant sterols and red yeast rice,” Dr Laffin indicated, emphasising that no musculoskeletal events were reported in the rosuvastatin arm.
“We should use these results to engage in evidence-based discussions with patients about the benefits of low dose statin and the lack of benefit that we see for these heart health supplements,“ Dr Laffin reviewed the public health importance of the trial.
- Laffin L. Effect of low-dose statin compared with placebo and six dietary supplements on lipid and inflammatory biomarkers: The SPORT randomised clinical trial. LBS.05, AHA Scientific Sessions 2022, 05–07 November, Chicago, USA.
Copyright ©2023 Medicom Medical Publishers
Posted on
Previous Article
« No sex differences in lipid-lowering effect and treatment benefit of PCSK9 inhibitors Next Article
Olpasiran leads to dramatic reductions in Lp(a) concentrations »
« No sex differences in lipid-lowering effect and treatment benefit of PCSK9 inhibitors Next Article
Olpasiran leads to dramatic reductions in Lp(a) concentrations »
Table of Contents: AHA 2022
Featured articles
What Is New in Heart Failure
Torsemide not superior to furosemide after hospitalisation for heart failure
IRONMAN failed primary endpoint but shows potential long-term benefits of iron repletion in HF patients
Up-titration of HF therapies following HF discharge saves lives
Hypertension: Novel Developments
The endothelin system: a new target for resistant high blood pressure
Can renal denervation lower BP on top of antihypertensive drugs?
Quadruple, ultra-low-dose treatment did not meet primary endpoint in hypertension
Mindfulness programme contributes to office blood pressure lowering
Interventional Cardiology in 2022
Grafting with the radial vein: an underrated option in CABG surgery?
Extracorporeal membrane oxygenation not superior to conservative therapy in cardiogenic shock
Surgery with adequate saphenous vein partly better than endovascular treatment in CLTI
Arrhythmia – State of the Art
First-line ablation limits progression to persistent AF
Doubling the dose of self-administered etripamil terminates PSVT
Novel Developments in Primary and Secondary Prevention
Grafting with the radial vein: an underrated option in CABG surgery?
Digitally delivered cognitive behavioural therapy successful in type 2 diabetes
Empagliflozin reduces risk of kidney disease progression and CV events in patients with CKD
RESPECT-EPA misses primary endpoint but hints towards improvements in CV outcomes by EPA
Pemafibrate fails to reduce cardiovascular events in diabetes but may benefit the liver
Dietary supplements not effective in lowering LDL-C, use of low-dose statins encouraged
No sex differences in lipid-lowering effect and treatment benefit of PCSK9 inhibitors
COVID-19 and the Heart
‘No’ to routine use of rivaroxaban in outpatients with COVID-19
COVID-19 pandemic: Older adults and those affected by the delta variant experienced increased cardiovascular morbidity and mortality
COVID-19 mRNA vaccination does not amplify risk of cardiovascular hospitalisation
Best of the Posters
Higher LDL-cholesterol levels linked to higher CVD mortality risk in the elderly
AF: Moderate alcohol intake possibly associated with a reduced mortality risk
Periodontitis: An independent risk factor for AF
Related Articles
November 28, 2022
AHA 2022 Highlights Podcast
January 11, 2023
Grafting with the radial vein: an underrated option in CABG surgery?
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com